Updated on October 31, 2025 Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others
We’re proud to celebrate Dr. Suzann Duan, an Assistant Professor in the Department of Pharmaceutical Sciences at UC Irvine, as the recipient of the 2025 Basic/Translational
By Anna Greene, PhD, NETRF Director of Research Dr. Benjamin Viglianti, recipient of a 2023 NETRF Investigator Award, is the senior author of a newly
NETRF is excited to announce that applications are now open for the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs), developed in partnership with
By Anna Greene, PhD, NETRF Director of Research What if small intestine neuroendocrine tumors (SI-NETs), often diagnosed in people over age 60, actually begin decades
By Anna Greene, PhD, NETRF Director of Research An important advancement in neuroendocrine neoplasm (NEN) patient care has been released: the Position Statement on Nutritional
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to